EXACT SCIENCES CORPEXASEarnings & Financial Report
Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.
EXAS Q4 2025 Key Financial Metrics
Revenue
$878.4M
Gross Profit
$615.8M
Operating Profit
$-82.6M
Net Profit
$-86.0M
Gross Margin
70.1%
Operating Margin
-9.4%
Net Margin
-9.8%
YoY Growth
23.1%
EPS
$-0.45
Financial Flow
EXACT SCIENCES CORP Q4 2025 Financial Summary
EXACT SCIENCES CORP reported revenue of $878.4M for Q4 2025, with a net profit of $-86.0M (-9.8% margin). Cost of goods sold was $262.6M, operating expenses totaled $698.4M.
Key Financial Metrics
| Total Revenue | $878.4M |
|---|---|
| Net Profit | $-86.0M |
| Gross Margin | 70.1% |
| Operating Margin | -9.4% |
| Report Period | Q4 2025 |
EXACT SCIENCES CORP Annual Revenue by Year
EXACT SCIENCES CORP annual revenue history includes year-by-year totals (for example, 2025 revenue was $3.2B).
| Year | Annual Revenue |
|---|---|
| 2025 | $3.2B |
| 2024 | $2.8B |
| 2023 | $2.5B |
| 2022 | $2.1B |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $637.5M | $699.3M | $708.7M | $713.4M | $706.8M | $811.1M | $850.7M | $878.4M |
| YoY Growth | 5.8% | 12.4% | 12.8% | 10.3% | 10.9% | 16.0% | 20.0% | 23.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $6.38B | $6.67B | $6.75B | $5.93B | $5.71B | $5.80B | $5.90B | $5.86B |
| Liabilities | $3.24B | $3.48B | $3.54B | $3.53B | $3.31B | $3.33B | $3.40B | $3.46B |
| Equity | $3.13B | $3.19B | $3.21B | $2.40B | $2.40B | $2.47B | $2.50B | $2.40B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-82.3M | $107.1M | $138.7M | $47.1M | $30.8M | $89.0M | $219.9M | $151.7M |
More Companies
CBU
COMMUNITY FINANCIAL SYSTEM, INC.
Revenue
$207.1M
Net Profit
$55.1M
QDEL
QuidelOrtho Corp
Revenue
$699.9M
Net Profit
$-733.0M
GDRX
GoodRx Holdings, Inc.
Revenue
$196.0M
Net Profit
$1.1M
PRTC
PureTech Health plc
CYH
COMMUNITY HEALTH SYSTEMS INC
Revenue
$3.1B
Net Profit
$130.0M
RCEL
AVITA Medical, Inc.
Revenue
$17.6M
Net Profit
$-11.6M
GOCO
GoHealth, Inc.
Revenue
$34.2M
Net Profit
$-165.8M